The patient was treated according to the AIEOP protocol LH-2004 for Hodgkin's lymphoma: six cycles of Cyclophosphamide, Vincristine, Procarbazine, and Prednisolone (COPP), with interval administration of Adriamycin, Bleomycin, and Vinblastin (ABV), followed by radiotherapy "mini-mantle" therapy (DFT 14.4 Gy).
The F18-FDG-PET study during chemotherapy showed complete resolution of the lymph-node uptake and a persistent accumulation of tracer in the tibia. The evaluation at the end of treatment indicated complete lymphoma remission (Fig. 4) . However, tibial uptake was unchanged (Fig. 5) .
Discussion
Diagnostic imaging methods, such as conventional radiographic, sonographic, and cross-sectional imaging, are excellent tools for evaluating Hodgkin's disease in pediatric patients (1) . F18-FDG-PET/CT recently achieved an important role in the initial staging of disease. This method is also important during chemotherapy (evaluation of early response), in radiotherapy planning, at the end of treatment, and during followup (1, 2, 6, 7) . However, FDG is not a tumor-specific substance. FDG accumulation may be observed in a variety of benign entities (2, 7) because activated granulocytes and macrophages may display signifi- Figure 3 . 14-year-old girl with nonossifying fibroma. AP radiograph of both tibias, showing an eccentric, lucent lesion in the distal right tibia with a well-demarcated, sclerotic border, consistent with a nonossifying fibroma.
cantly increased glucose consumption (infection, G-CSF administration, radiation therapy, fracture) (8) . FDG biodistribution also can be affected by various physiologic factors, such as brown adipose tissue (2), blood glucose levels, and muscle uptake (9) . All these conditions may give rise to false-positive results in staging, in evaluation of treatment response, and in post-treatment assessment and followup.
Nonossifying fibroma (NOF) is a common benign finding encountered in radiology. It is a well-circumscribed solitary proliferation of fibrous tissue. NOF is more common in males than females, and may occur in as many as 35% of all children (10) (11) (12) , with 75% of cases presenting in the second decade of life (10, 11, 13) . Clinically, NOF is asymptomatic and is usually discovered by chance on a radiograph. NOF is usually located in the metaphysis or diametaphyseal junction of the femur or tibia (10) (11) (12) (13) (14) (15) . In general, NOF regresses spontaneously. During the involutional phase, osteoblastic activity increases as the lesion is replaced by new bone (13) . Conventional radiography, CT, and MRI characteristics of NOF have been extensively studied (10) (11) (12) (13) (14) (15) . On unenhanced radiographs, a nonossifying fibroma appears as an eccentric radiolucent lesion with thinned cortex, a multilocular appearance, and often a sclerotic margin. Some authors have reported NOF as being metabolically active on F18-FDG-PET images (10, 13) . Such activity, probably independent of lesion size, varies among patients and over time, as indicated by their F18-FDG uptake on PET (13) .
Conclusion
The PET appearance of nonossifying fibroma can mimic bone metastasis (13) . The possible mechanism for F18-FDG uptake in such cases is similar to that for acute fractures, consisting of increased blood flow and osteoblastic activity.
When PET reveals metabolically active osseous abnormalities in children who are at risk for bone metastases, benign fibro-osseous lesions should be considered in the differential diagnosis before additional diagnostic procedures are undertaken. Information obtained by the CT component of the PET/CT study and by conventional radiography is essential to characterize the nature of these lesions and to prevent erroneous interpretations of the F18-FDG uptakes. 
